Is Esprinet S.p.A. (BIT:PRT) Potentially Undervalued?
Esprinet S.p.A. (BIT:PRT), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the past couple of months on the BIT. The company is now trading at yearly-high levels following the recent surge in its share price. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let’s take a look at Esprinet’s outlook and value based on the most recent financial data to see if the opportunity still exists.
What's The Opportunity In Esprinet?
Esprinet appears to be overvalued by 24% at the moment, based on our discounted cash flow valuation. The stock is currently priced at €7.71 on the market compared to our intrinsic value of €6.22. Not the best news for investors looking to buy! But, is there another opportunity to buy low in the future? Since Esprinet’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
Check out our latest analysis for Esprinet
What does the future of Esprinet look like?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 40% over the next couple of years, the future seems bright for Esprinet. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.
What This Means For You
Are you a shareholder? It seems like the market has well and truly priced in PRT’s positive outlook, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe PRT should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.
Are you a potential investor? If you’ve been keeping tabs on PRT for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for PRT, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.
If you'd like to know more about Esprinet as a business, it's important to be aware of any risks it's facing. To that end, you should learn about the 2 warning signs we've spotted with Esprinet (including 1 which doesn't sit too well with us).
If you are no longer interested in Esprinet, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.